全球成像流式细胞技术市场规模（按产品、应用、技术、地区和预测）

成像流式细胞技术市场规模及预测

2023 年成像流式细胞技术市场规模价值 424.8 亿美元，预计到 2032 年将达到 1,036.1 亿美元，2026 年至 2032 年的复合年增长率为 11.79%。

成像流式细胞技术(IFC) 是一项革命性的技术，它将传统流式细胞技术的定量能力与数位显微镜的视觉深度相结合，可以同时对大量单一细胞进行详细分析和成像。

将流式细胞技术与成像相结合的概念自 20 世纪 70 年代末就已出现，但该领域的一些早期发展可以追溯到罗彻斯特大学的 Leon Wheeless，他致力于开发功能性成像流式细胞仪。

这项开创性的工作为现代 IFC 系统奠定了基础，该系统后来不断发展，可以提供高解析度影像并实现复杂的细胞分析。

近年来，IFC 因其能够从有限的样本量中提取更全面的数据（尤其是在单细胞层级）而广受欢迎。这种能力在免疫学、肿瘤学和干细胞研究等领域至关重要，因为了解单一细胞的特性至关重要。

IFC 将流式细胞技术的高通量和定量优势与显微镜的可视化数据相结合，为研究人员提供了详细研究细胞形态、表型和功能的强大工具，使其在研究和临床诊断应用中都具有不可估量的价值。

全球成像流式细胞技术市场动态

影响全球成像流式细胞技术市场的关键市场动态是：

关键市场驱动因素

更重视免疫学和免疫肿瘤学研究：美国卫生研究院 (NIH) 预计，2020 年至 2023 年间，免疫学研究津贴将增加 35%。 2020 年至 2022 年间，涉及免疫肿瘤学流式细胞技术技术的临床试验数量将增加 45%。 2020 年至 2023 年，全球免疫学实验室对成像流式细胞技术的采用率增加了 28%。

流式细胞技术技术在研究和临床试验中的应用日益广泛：根据 Verified Market Research Analyst 的数据，2023 年全球流式细胞技术市场价值将达到 46.8554 亿美元，到 2032 年将达到 80.66 亿美元。 2020 年至 2022 年，流式细胞技术在药物发现和开发活动中的使用增加了 32%。 2020 年至 2022 年，包含流式细胞技术的科学论文数量增加了 25%。

成像流式细胞技术的技术进步：2020 年至 2022 年，成像流式细胞技术技术研发的投资成长了 42%。 2020 年至 2023 年，成像流式细胞技术市场新产品发布数量增加了 38%。 2020 年至 2022 年，全球成像流式细胞技术仪仪器销售额成长了 27%。 2020 年至 2022 年，人工智慧和机器学习在成像流式细胞技术分析中的整合成长了 33%。

主要挑战

数据分析的复杂性和对专业知识的需求：从 2020 年到 2022 年，成像流式细胞技术数据分析所需的平均时间增加了 28%。从 2020 年到 2023 年，全球缺乏具备成像流式细胞技术资料分析专业知识的生物资讯专业人员。从 2020 年到 2022 年，用于成像流式细胞技术数据分析的专用软体的成本增加了 25%。到 2022 年，45% 的研究人员将报告解释成像流式细胞技术产生的复杂数据的挑战。

设备和维护成本高：从 2020 年到 2022 年，成像流式细胞技术仪的平均价格上涨了 18%。从 2020 年到 2023 年，成像流式细胞技术仪的年度维护服务成本上涨了 22%。从 2020 年到 2022 年，成像流式细胞技术解决方案的总拥有成本上涨了 30%。 38% 的中小型实验室认为预算限制是 2022 年采用成像流式细胞技术的主要障碍。

熟练技术人员短缺：2020 年至 2023 年，全球操作和维护成像流式细胞技术仪的训练有素的人员短缺增加了 27%。从 2020 年到 2022 年，训练成像流式细胞技术仪新用户所需的平均时间增加了 20%。 42% 的成像流式细胞技术使用者表示，到 2022 年，他们将很难找到熟练的技术人员来支援他们的仪器。

主要趋势

高解析度成像的进步：从 2020 年到 2022 年，分辨率为 0.5 μm 或更高的成像流式细胞技术仪仪器的数量增加了 55%。从 2020 年到 2023 年，构造化照明显微镜 (SIM) 等超高解析度成像技术在成像流式细胞技术中的应用成长了 42%。从 2020 年到 2022 年，利用高解析度成像流式细胞技术进行细胞形态分析的研究论文增加了 35%。

人工智慧与机器学习的融合：从 2020 年到 2022 年，人工智慧驱动的影像分析演算法在成像流式细胞技术软体中的应用成长了 65%。从 2020 年到 2023 年，机器学习模型在成像流式细胞技术中用于自动细胞分类和识别的应用增加了 52%。 2022 年，人工智慧成像流式细胞技术解决方案的研发投资达到 8,500 万美元，高于 2020 年的 5,200 万美元。 48% 的成像流式细胞技术用户报告称，由于 2022 年人工智慧和机器学习技术的融合，数据分析效率有所提高。

微型可携式成像流式细胞技术：紧凑型桌上型成像流式细胞技术仪的销量从 2020 年到 2022 年增长了 38%。预计从 2020 年到 2023 年，可携式手持式成像流式细胞技术仪的开发将成长 25%。与 2020 年相比，2022 年微型成像流式细胞技术解决方案在就地检验和现场应用中的采用率将增加 32%。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查时间表
• 先决条件
• 限制

第二章调查方法

• 资料探勘
• 二次调查
• 初步调查
• 专家建议
• 品质检查
• 最终审核
• 数据三角测量
• 自下而上的方法
• 自上而下的方法
• 研究流程
• 资料来源

第三章执行摘要

• 成像流式细胞技术市场概览
• 成像流式细胞技术市场製图
• 成像流式细胞技术的绝对商机
• 成像流式细胞技术市场的吸引力
• 未来市场机会
• 全球市场区隔

第四章 市场展望

• 成像流式细胞技术市场转型
• 成像流式细胞技术市场展望
• 市场驱动因素
  • 研究和学术领域对成像流式细胞技术的需求日益增长
  • 随着人工智慧平台越来越多地用于成像流式细胞仪，收益来源不断扩大
• 限制因素
  • 产品成本高
  • 新兴国家购买量有限
• 机会
  • 片上多成像流式细胞技术的发展推动了市场成长
• COVID19的影响
• 波特五力分析
  • 新进入者的威胁
  • 替代品的威胁
  • 供应商的议价能力
  • 买家的议价能力
  • 竞争对手之间的竞争强度
• 价值链分析
• 宏观经济分析

第五章 成像流式细胞技术市场（按产品）

• 概述
• 软体与服务
• 套件和试剂
• 装置

第六章 成像流式细胞技术市场（依应用）

• 概述
• 学术研究所
• 医院及临床检测机构
• 製药和生物技术公司

7. 成像流式细胞技术市场（按技术）

• 以微珠为基础
• 基于细胞的流式细胞技术

8. 成像流式细胞技术市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 拉丁美洲
• 巴西
• 阿根廷
• 其他拉丁美洲
  • 中东和非洲
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 其他中东和非洲地区

第九章 竞争态势

• 概述
• 各公司市场排名分析
• 区域足迹
• 公司在各行业的足迹
• 王牌矩阵
  • 积极的
  • 前线
  • 新兴
  • 创新者

第十章 公司简介

• LUMINEX CORPORATION
• MILTENYI BIOTEC
• DANAHER CORPORATION
• CORIOLIS PHARMA
• SYSMEX
• THERMO FISHER SCIENTIFIC
• YOKOGAWA FLUID IMAGING TECHNOLOGIES, INC.
• APOGEE FLOW SYSTEMS LTD.
• NEXCELOM BIOSCIENCE LLC
• BIO-RAD LABORATORIES, INC.

Imaging Flow Cytometry Market Size And Forecast

The Imaging Flow Cytometry Market size was valued at USD 42.48 Billion in 2023 and is projected to reach USD 103.61 Billion by 2032, growing at a CAGR of 11.79% from 2026 to 2032.

Imaging Flow Cytometry (IFC) is an innovative technique that merges the quantitative power of traditional flow cytometry with the visual depth of digital microscopy, enabling the detailed analysis and imaging of numerous individual cells simultaneously.

While the concept of integrating flow cytometry with imaging has been explored since the late 1970s, early developments in this field include efforts by Leon Wheeless at the University of Rochester, who worked on creating functional imaging flow cytometers.

This pioneering work laid the foundation for modern IFC systems, which have since evolved to provide high-resolution images and enable complex cell analysis.

In recent years, IFC has gained popularity due to its ability to extract more comprehensive data from limited sample volumes, especially at the single-cell level. This capability is critical in fields such as immunology, oncology, and stem cell research, where understanding individual cell characteristics is essential.

By combining the strengths of flow cytometry high-throughput and quantitative measurement with the visual data of microscopy, IFC offers researchers a powerful tool for studying cell morphology, phenotype, and function in intricate detail, making it invaluable in both research and clinical diagnostics.

Global Imaging Flow Cytometry Market Dynamics

The key market dynamics that are shaping the global imaging flow cytometry market include:

Key Market Drivers

Increasing Focus on Immunology and Immuno-oncology Research: Funding for immunology research increased by 35% at the National Institutes of Health (NIH) in the US between 2020 and 2023. The number of clinical trials involving flow cytometry techniques in immuno-oncology increased by 45% from 2020 to 2022. The adoption of imaging flow cytometry in immunology laboratories grew by 28% globally between 2020 and 2023.

Rising Adoption of Flow Cytometry Techniques in Research and Clinical Trials: According to the Verified Market Research Analyst, the Global Flow Cytometry Market was valued at USD 4685.54 Million in 2023 to reach a valuation of USD 8066 Million by 2032. Utilization of flow cytometry in drug discovery and development activities increased by 32% from 2020 to 2022. The number of scientific publications involving flow cytometry rose by 25% between 2020 and 2022.

Technological Advancements in Imaging Flow Cytometry: Investment in R&D for imaging flow cytometry technologies grew by 42% from 2020 to 2022. The number of new product launches in the imaging flow cytometry market increased by 38% between 2020 and 2023. Imaging flow cytometry instrument sales grew by 27% globally from 2020 to 2022. The integration of artificial intelligence and machine learning in imaging flow cytometry analysis increased by 33% from 2020 to 2022.

Key Challenges

Data Analysis Complexity and Expertise Requirements: The average time required for data analysis in imaging flow cytometry increased by 28% from 2020 to 2022. The global shortage of bioinformatics professionals with expertise in imaging flow cytometry data analysis grew by 32% between 2020 and 2023. The cost of specialized software for imaging flow cytometry data analysis increased by 25% from 2020 to 2022. 45% of researchers reported challenges in interpreting the complex data generated by imaging flow cytometry in 2022.

High Instrument and Maintenance Costs: The average price of imaging flow cytometry instruments increased by 18% from 2020 to 2022. The annual maintenance and service costs for imaging flow cytometry systems grew by 22% between 2020 and 2023. The total cost of ownership for imaging flow cytometry solutions increased by 30% from 2020 to 2022. 38% of small and medium-sized research laboratories reported budget constraints as a significant barrier to adopting imaging flow cytometry in 2022.

Limited Availability of Skilled Technicians: The global shortage of trained personnel for the operation and maintenance of imaging flow cytometry instruments grew by 27% from 2020 to 2023. The average time required for training new users on imaging flow cytometry systems increased by 20% between 2020 and 2022. 42% of imaging flow cytometry users reported challenges in finding qualified technicians to support their instrumentation in 2022.

Key Trends

Advancements in High-Resolution Imaging: The number of imaging flow cytometry instruments with a resolution of 0.5 μm or better increased by 55% from 2020 to 2022. The adoption of super-resolution imaging techniques, such as structured illumination microscopy (SIM), in imaging flow cytometry grew by 42% between 2020 and 2023. Research publications utilizing high-resolution imaging flow cytometry for cellular morphology analysis increased by 35% from 2020 to 2022.

Integration of Artificial Intelligence and Machine Learning: The incorporation of AI-powered image analysis algorithms in imaging flow cytometry software increased by 65% from 2020 to 2022. The use of machine learning models for automated cell classification and identification in imaging flow cytometry grew by 52% between 2020 and 2023. Investment in R&D for AI-enabled imaging flow cytometry solutions reached $85 million in 2022, up from USD 52 Million in 2020. 48% of imaging flow cytometry users reported improved data analysis efficiency due to the integration of AI and ML technologies in 2022.

Miniaturization and Portable Imaging Flow Cytometry: The sales of compact, benchtop imaging flow cytometry instruments increased by 38% from 2020 to 2022. The development of portable, handheld imaging flow cytometry devices grew by 25% between 2020 and 2023. Adoption of miniaturized imaging flow cytometry solutions in point-of-care testing and field applications increased by 32% in 2022 compared to 2020.

Global Imaging Flow Cytometry Market Regional Analysis

Here is a more detailed regional analysis of the global imaging flow cytometry market:

North America

North America substantially dominates the Global Imaging Flow Cytometry Market driven by the robust healthcare expenditure and infrastructure.

The healthcare expenditure in the United States increased by 9.7% from 2020 to 2022, reaching USD 4.1 Trillion.

Canada's healthcare spending grew by 6.2% between 2020 and 2022, totaling $308 billion.

The number of accredited medical and clinical laboratories in North America increased by 15% from 2020 to 2023.

Investment in biomedical research and development in the US increased by 12% from 2020 to 2022.

Adoption of imaging flow cytometry instruments in the US and Canada increased by 32% between 2020 and 2023.

The number of academic and pharmaceutical research institutions utilizing imaging flow cytometry in North America rose by 28% from 2020 to 2022.

45% of global imaging flow cytometry system installations were in North America in 2022, up from 40% in 2020.

North America accounted for 55% of the global imaging flow cytometry market share in 2022, up from 50% in 2020.

The US FDA approved 20% more imaging flow cytometry-based diagnostic kits and reagents from 2020 to 2022.

Major imaging flow cytometry vendors, such as Luminex, Amnis (part of Merck), and Nexcelom Bioscience, have a significant presence in North America.

Government funding for imaging flow cytometry research and development in the US and Canada increased by 18% from 2020 to 2023.

Asia Pacific

Asia Pacific is anticipated to witness the fastest growth in the Global Imaging Flow Cytometry Market during the forecast period owing to the increasing biomedical research and clinical trials.

The Asia Pacific biotech and pharmaceutical R&D spending grew by 27% from 2020 to 2022.

The number of clinical trials involving flow cytometry techniques in the APAC region increased by 35% between 2020 and 2023.

Funding for immunology and oncology research in countries like China, Japan, and India rose by 42% from 2020 to 2022.

The APAC imaging flow cytometry market share increased from 35% in 2020 to 42% in 2022.

Healthcare spending in the Asia Pacific region grew by 15.4% from 2020 to 2022, reaching USD 2.1 Trillion.

The number of accredited medical laboratories in APAC increased by 18% between 2020 and 2023.

Investment in healthcare technology, including flow cytometry, increased by 28% in the APAC region from 2020 to 2022.

Government initiatives to improve diagnostic capabilities drove a 32% rise in imaging flow cytometry adoption from 2020 to 2022.

The demand for flow cytometry-based COVID-19 diagnostics and research grew by 65% in APAC from 2020 to 2022.

Imaging flow cytometry applications in vaccine development and immunology studies increased by 55% in the APAC region between 2020 and 2022.

Investment in imaging flow cytometry instrumentation by public and private healthcare institutions in the APAC region rose by 48% from 2020 to 2022.

The Asia Pacific imaging flow cytometry market is expected to grow at a CAGR of 12.6% from 2020 to 2023, outpacing other regions.

Global Imaging Flow Cytometry Market: Segmentation Analysis

The Global Imaging Flow Cytometry Market is segmented based on Product, Application, Technology, And Geography.

Imaging Flow Cytometry Market, By Product

• Software & Services
• Kits & Reagents
• Instruments

Based on the Product, the Global Imaging Flow Cytometry Market is bifurcated into Software & Services, Kits & Reagents, and Instruments. The instrument segment significantly dominates the global imaging flow cytometry market, driven by technological advancements like higher-resolution imaging and faster acquisition rates, which enhance data accuracy and analysis efficiency. These innovations support expanding applications across diverse research fields, including immunology, cancer biology, and stem cell research, where detailed cellular imaging is essential.

Imaging Flow Cytometry Market, By Application

• Academic & Research Institutes
• Hospitals & Clinical Testing Laboratories
• Pharmaceutical & Biotechnology Companies

Based on the Application, the Global Imaging Flow Cytometry Market is bifurcated into Academic & Research Institutes, Hospitals & Clinical Testing Laboratories, and Pharmaceutical & Biotechnology Companies. The Academic and Research Institutes segment dominates the global imaging flow cytometry market, driven by extensive research in fields like immunology, cancer biology, and stem cell studies. Rising demand for advanced cell analysis techniques, coupled with government funding and grants supporting research initiatives, further boosts the segment's prominence in this market.

Imaging Flow Cytometry Market, By Technology

• Bead-based
• Cell-based Flow Cytometry

Based on the Technology, the Global Imaging Flow Cytometry Market is bifurcated into Bead-based and Cell-based Flow Cytometry. The cell-based flow cytometry segment dominates the lobal imaging flow cytometry market, fueled by its ability to study cellular morphology, protein expression, and functional properties in detail. The growing demand for advanced cell analysis techniques across diverse research fields and its increasing adoption in clinical diagnostics further enhance this segment's leadership in the market.

Imaging Flow Cytometry Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Imaging Flow Cytometry Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America substantially dominates the Global Imaging Flow Cytometry Market driven by the robust healthcare expenditure and infrastructure. The healthcare expenditure in the United States increased by 9.7% from 2020 to 2022, reaching USD 4.1 Trillion. Canada's healthcare spending grew by 6.2% between 2020 and 2022, totaling USD 308 Billion. The number of accredited medical and clinical laboratories in North America increased by 15% from 2020 to 2023. Investment in biomedical research and development in the US increased by 12% from 2020 to 2022. Adoption of imaging flow cytometry instruments in the US and Canada increased by 32% between 2020 and 2023.

Key Players

The "Global Imaging Flow Cytometry Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Luminex Corporation, Miltenyi Biotec, Danaher Corporation, Coriolis Pharma, Sysmex, Thermo Fisher, Apogee Flow Systems Ltd., Yokogawa Fluid Imaging Technologies, Inc., Nexcelom Bioscience LLC, Molecular Devices LLC.

• This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Imaging Flow Cytometry Market Key Developments

• In May 2024, Luminex Corporation announced the launch of their next-generation imaging flow cytometer, which boasts 50% higher throughput and superior AI-powered data analytics capabilities.
• In January 2024, Sysmex Corporation announced the acquisition of a top European imaging flow cytometry technology firm therefore boosting its product line and expanding its global footprint.
• In June 2023, Miltenyi Biotec announced a collaboration with a prominent US academic university to develop AI-driven algorithms for automatic cell classification in image flow cytometry applications.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL IMAGING FLOW CYTOMETRY MARKET OVERVIEW
• 3.2 GLOBAL IMAGING FLOW CYTOMETRY ECOLOGY MAPPING
• 3.3 GLOBAL IMAGING FLOW CYTOMETRY ABSOLUTE MARKET OPPORTUNITY
• 3.4 GLOBAL IMAGING FLOW CYTOMETRY MARKET ATTRACTIVENESS
• 3.5 GLOBAL IMAGING FLOW CYTOMETRY MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.6 GLOBAL IMAGING FLOW CYTOMETRY MARKET, BY COMPONENT (USD MILLION)
• 3.7 GLOBAL IMAGING FLOW CYTOMETRY MARKET, BY APPLICATION (USD MILLION)
• 3.8 FUTURE MARKET OPPORTUNITIES
• 3.9 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

• 4.1 GLOBAL IMAGING FLOW CYTOMETRY MARKET EVOLUTION
• 4.2 GLOBAL IMAGING FLOW CYTOMETRY MARKET OUTLOOK
• 4.3 MARKET DRIVERS
  • 4.3.1 THE GROWING NEED FOR IMAGING FLOW CYTOMETRY IN RESEARCH AND ACADEMIA
  • 4.3.2 RISING INCORPORATION OF AI PLATFORMS FOR IMAGING FLOW CYTOMETER TO WIDEN THE REVENUE GATE
• 4.4 RESTRAINTS
  • 4.4.1 SIGNIFICANT PRODUCT COST TO HAMPER ADOPTION OF IMAGING FLOW CYTOMETRY
  • 4.4.2 LIMITED PURCHASE IN DEVELOPING COUNTRIES
• 4.5 OPPORTUNITY
  • 4.5.1 DEVELOPMENT OF ON CHIP MULTI IMAGING FLOW CYTOMETRY TO OPEN GATES FOR THRIVING MARKET
• 4.6 COVID19 IMPACT
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 THREAT OF SUBSTITUTES
  • 4.7.3 BARGAINING POWER OF SUPPLIERS
  • 4.7.4 BARGAINING POWER OF BUYERS
  • 4.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 MACROECONOMIC ANALYSIS

5 IMAGING FLOW CYTOMETRY MARKET, BY PRODUCT

• 5.1 OVERVIEW
• 5.2 SOFTWARE & SERVICES
• 5.3 KITS & REAGENTS
• 5.4 INSTRUMENTS

6 IMAGING FLOW CYTOMETRY MARKET, BY APPLICATION

• 6.1 OVERVIEW
• 6.2 ACADEMIC & RESEARCH INSTITUTES
• 6.3 HOSPITALS & CLINICAL TESTING LABORATORIES
• 6.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

7 IMAGING FLOW CYTOMETRY MARKET, BY TECHNOLOGY

• 7.1 BEAD-BASED
• 7.2 CELL-BASED FLOW CYTOMETRY

8 IMAGING FLOW CYTOMETRY MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA-PACIFIC
• 8.5 LATIN AMERICA
• 8.6 BRAZIL
• 8.7 ARGENTINA
• 8.8 REST OF LATIN AMERICA
  • 8.8.1 MIDDLE EAST AND AFRICA
• 8.9 UAE
• 8.10 SAUDI ARABIA
• 8.11 SOUTH AFRICA
• 8.12 REST OF MEA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPANY MARKET RANKING ANALYSIS
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 COMPANY INDUSTRY FOOTPRINT
• 9.5 ACE MATRIX
  • 9.5.1 ACTIVE
  • 9.5.2 CUTTING EDGE
  • 8.5.3 EMERGING
  • 8.5.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 LUMINEX CORPORATION
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 COMPANY INSIGHTS
  • 10.1.3 SEGMENT BREAKDOWN
  • 10.1.4 PRODUCT BENCHMARKING
  • 10.1.5 CURRENT FOCUS & STRATEGIES
  • 10.1.6 THREAT FROM COMPETITION
  • 10.1.7 SWOT ANALYSIS
• 10.2 MILTENYI BIOTEC
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 COMPANY INSIGHTS
  • 10.2.3 PRODUCT BENCHMARKING
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 CURRENT FOCUS & STRATEGIES
  • 10.2.6 THREAT FROM COMPETITION
  • 10.2.7 SWOT ANALYSIS
• 10.3 DANAHER CORPORATION
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 COMPANY INSIGHTS
  • 10.3.3 SEGMENT BREAKDOWN
  • 10.3.4 CURRENT FOCUS & STRATEGIES
  • 10.3.5 THREAT FROM COMPETITION
  • 10.3.6 SWOT ANALYSIS
• 10.4 CORIOLIS PHARMA
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 COMPANY INSIGHTS
  • 10.4.3 CURRENT FOCUS & STRATEGIES
  • 10.4.4 THREAT FROM COMPETITION
  • 10.4.5 SWOT ANALYSIS
• 10.5 SYSMEX
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 COMPANY INSIGHTS
  • 10.5.3 SEGMENT BREAKDOWN
  • 10.5.4 PRODUCT BENCHMARKING
  • 10.5.5 CURRENT FOCUS & STRATEGIES
  • 10.5.6 THREAT FROM COMPETITION
  • 10.5.7 SWOT ANALYSIS
• 10.6 THERMO FISHER SCIENTIFIC
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 COMPANY INSIGHTS
  • 10.6.3 SEGMENT BREAKDOWN
  • 10.6.4 PRODUCT BENCHMARKING
  • 10.6.5 CURRENT FOCUS & STRATEGIES
  • 10.6.6 THREAT FROM COMPETITION
  • 10.6.7 SWOT ANALYSIS
  • 10.6.8 KEY DEVELOPMENTS
• 10.7 YOKOGAWA FLUID IMAGING TECHNOLOGIES, INC.
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 COMPANY INSIGHTS
  • 10.7.3 PRODUCT BENCHMARKING
  • 10.7.4 KEY DEVELOPMENTS
• 10.8 APOGEE FLOW SYSTEMS LTD.
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 COMPANY INSIGHTS
  • 10.8.3 PRODUCT BENCHMARKING
• 10.9 NEXCELOM BIOSCIENCE LLC
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 COMPANY INSIGHTS
  • 10.9.3 PRODUCT BENCHMARKING
• 10.10 BIO-RAD LABORATORIES, INC.
  • 10.10.1 BIO-RAD LABORATORIES, INC.
  • 10.10.2 COMPANY INSIGHTS
  • 10.10.3 SEGMENT BREAKDOWN
  • 10.10.4 PRODUCT BENCHMARKING